@article {7895,
	title = {Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib},
	journal = {Haematologica},
	volume = {93},
	year = {2008},
	note = {Cited By :20Export Date: 21 February 2017},
	month = {2008},
	pages = {451 - 454},
	abstract = {Neoangiogenesis is involved in the pathophysiology of multiple myeloma and angiopoietins possibly contribute to myeloma-induced neovascularization. Bortezomib{\textquoteright}s antineoplastic potential includes an anti-angiogenic effect. We determined serum levels of angiopoietin-1 and angiopoietin-2 with ELISA pre- and post-bortezomib administration in 35 patients with relapsed/refractory multiple myeloma. Pre-bortezomib, serum angiopoietin-1 levels did not differ in patients and in healthy individuals, while serum angiopoietin-2 levels were elevated. Corresponding serum angiopoietin-1/angiopoietin-2 ratio was reduced in patients compared with controls. After treatment, serum angiopoietin-1 levels increased, while serum angiopoietin-2 levels decreased, therefore the angiopoietin-1/ angiopoietin-2 ratio increased and normalized. This increase was significant in patients who responded to treatment. In conclusion, angiopoietin-1/angiopoietin- 2 ratio normalization reflected response to bortezomib. {\textcopyright}2008 Ferrata Storti Foundation.},
	keywords = {bortezomib, myeloma, Serum Ang-1/Ang-2 ratio, Serum angiopoietins},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-40849146069\&doi=10.3324\%2fhaematol.11852\&partnerID=40\&md5=469d8cdec52714daeeecf22801d5a7bd},
	author = {Anargyrou, K. and Terpos, E. and Vassilakopoulos, T.P. and Pouli, A. and Sachanas, S. and Tzenou, T. and Masouridis, S. and Christoulas, D. and Angelopoulou, M.K. and Dimitriadou, E.M. and Kalpadakis, C. and Tsionos, K. and Panayiotidis, P. and Dimopoulos, M.A. and Pangalis, G.A. and Kyrtsonis, M.-C.}
}
